SEC Form ARS filed by Rapid Micro Biosystems Inc.
$RPID
Biotechnology: Laboratory Analytical Instruments
Industrials
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2022 | Overweight → Neutral | JP Morgan | |
| 3/7/2022 | $11.00 → $10.00 | Equal-Weight | Morgan Stanley |
| 2/15/2022 | $24.00 → $11.00 | Equal-Weight | Morgan Stanley |
| 11/15/2021 | $26.00 → $24.00 | Equal-Weight | Morgan Stanley |
| 8/9/2021 | Outperform | Cowen | |
| 8/9/2021 | $26.00 | Equal-Weight | Morgan Stanley |
| 8/9/2021 | $28.00 | Buy | Stifel |
| 8/9/2021 | $30.00 | Overweight | JP Morgan |
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar
LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S
MALVERN, Pa., April 4, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry-leading provider of drug discovery services, today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company's next stage of growth. "We are thrilled to welcome Rich, a seasoned healthcare finance and operations executive, to the Executive Committee of Reaction Biology," said John H. Johnson, Chief Executive Officer and Director of Reaction Biology. "Having managed large, global biopharmaceut
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral
Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $10.00 from $11.00 previously
Morgan Stanley reiterated coverage of Rapid Micro Biosystems with a rating of Equal-Weight and set a new price target of $11.00 from $24.00 previously
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout Achieved inflection in gross margins to positive 8%, representing a significant company milestone and a 35 percentage point improvement compared to the third quarter of 2023Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 2
LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024. In conjunction with the release, the Company's management team will host a webcast conference call beginning at 9:00 a.m. ET on Friday, November 1, 2024. The live audio webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. A
Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023150th Growth Direct® system placed with an existing top 15 global pharma customer First Growth Direct Rapid Sterility system placed with an existing top 10 global pharma customerGross margin improved by 35 percentage points compared to the second quarter of 2023, and by 24 percentage points compared to the first quarter of 2024Announces operational efficiency program that is expected to enable the Company to achieve positive cash flow without additional financingReaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compa
LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2024 Healthcare Conference. Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 30-minute question-and-answer session with the host analyst on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021 Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout Achieved inflection in gross margins to positive 8%, representing a significant company milestone and a 35 percentage point improvement compared to the third quarter of 2023Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 2
LEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024. In conjunction with the release, the Company's management team will host a webcast conference call beginning at 9:00 a.m. ET on Friday, November 1, 2024. The live audio webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. A
Rapid Micro Biosystems (NASDAQ:RPID) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 3.13 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $5.611 million which beat the analyst consensus estimate of $5.500 million by 2.02 percent. This is a 11.44 percent increase over sales of $5.035 million the same period last year.
Shares of Apple Inc. (NASDAQ:AAPL) rose sharply in today's pre-market trading after the company reported better reported better-than-expected results for its second quarter. The company announced a $110-billion stock buyback program and a one-penny-per-share increase in its quarterly dividend. Apple shares jumped 5.9% to $183.24 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Vaxxinity, Inc. (NASDAQ:VAXX) gained 45.8% to $0.1519 in pre-market trading after falling 9% on Thursday. Vaxxinity recently announced its intention to voluntarily delist and deregister its Class A common stock. El Pollo Loco Holdings, Inc. (NASDAQ:LOCO) gained
Companies Reporting Before The Bell • McEwen Mining (NYSE:MUX) is estimated to report quarterly loss at $0.28 per share on revenue of $71.72 million. • PropertyGuru Group (NYSE:PGRU) is estimated to report quarterly loss at $0.02 per share on revenue of $31.70 million. • Plug Power (NASDAQ:PLUG) is projected to report quarterly loss at $0.44 per share on revenue of $236.44 million. • CSI Compressco (NASDAQ:CCLP) is projected to report earnings for its fourth quarter. • EchoStar (NASDAQ:SATS) is likely to report quarterly loss at $0.10 per share on revenue of $3.89 billion. • Rapid Micro Biosystems (NASDAQ:RPID) is expected to report quarterly loss at $0.30 per share on revenue of $6.15